Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2023 | Updates in the genomics of SMM & multiple myeloma

In this session chaired by Leif Bergsagel, MD, Mayo Clinic, Phoenix, AZ, Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, and Niels Weinhold, PhD, University Hospital Heidelberg, Heidelberg, Germany, explore updates in our understanding of the genomics of smoldering multiple myeloma (SMM) and multiple myeloma. The experts first comment on the definition of smoldering myeloma, before discussing the transition from FISH to next-generation sequencing (NGS) and novel prognostic features to risk stratify patients. The experts then move on to the prognostic value of del(17p) and TP53 mutations, and finish by commenting on clonal substructure and drivers of relapse. This session was filmed at the 16th International Workshop on Multiple Myeloma (iwMyeloma) held in Madrid, Spain.